Wellington Biomedical Innovation Master Investors (Cayman) II L.P. — SEC Form 4 filings

SEC reporting owner CIK 1903360. 4 Form 4 filings on record with FilingPulse; latest filed 2026-05-01.

Transaction summary — filings shown

Covers all 4 filings on record, filed 2024-09-17 to 2026-05-01. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
MBX Biosciences, Inc. (MBX)10% owner14
Avalyn Pharma Inc. (AVLN)10% owner13
Metsera, Inc. (MTSR)10% owner12
Upstream Bio, Inc. (UPB)10% owner12

Form 4 filings — Wellington Biomedical Innovation Master Investors (Cayman) II L.P.

FiledFormIssuerReported transactionsSource
2026-05-014Avalyn Pharma Inc. (AVLN)Conversion (C): 1,275,486 · Conversion (C): 20,482,289 (derivative) @ $0 · Conversion (C): 4,060,259 (derivative) @ $0EDGAR
2025-02-034Metsera, Inc. (MTSR)Conversion (C): 1,857,699 · Conversion (C): 4,365,079 (derivative) @ $0EDGAR
2024-10-154Upstream Bio, Inc. (UPB)Conversion (C): 894,733 · Conversion (C): 852,940 (derivative) @ $0EDGAR
2024-09-174MBX Biosciences, Inc. (MBX)Conversion (C): 1,386,335 · Conversion (C): 403,787 · Conversion (C): 16,666,666 (derivative) @ $0 · Conversion (C): 4,854,368 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1903360 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →